IRIS
SANTILLI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.498
EU - Europa 4.650
AS - Asia 2.788
Continente sconosciuto - Info sul continente non disponibili 14
SA - Sud America 5
AF - Africa 4
OC - Oceania 4
Totale 12.963
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.467
CN - Cina 990
IE - Irlanda 947
SG - Singapore 906
UA - Ucraina 774
IT - Italia 686
SE - Svezia 666
TR - Turchia 662
GB - Regno Unito 450
FR - Francia 361
DE - Germania 293
FI - Finlandia 205
IN - India 180
RU - Federazione Russa 153
CA - Canada 25
NL - Olanda 21
PL - Polonia 18
VN - Vietnam 18
BE - Belgio 16
CZ - Repubblica Ceca 16
EU - Europa 11
AT - Austria 9
HK - Hong Kong 9
IR - Iran 8
AL - Albania 6
RO - Romania 6
JP - Giappone 5
LT - Lituania 5
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AU - Australia 3
BZ - Belize 3
CH - Svizzera 3
DK - Danimarca 3
GR - Grecia 3
HU - Ungheria 3
IL - Israele 3
LK - Sri Lanka 3
AZ - Azerbaigian 2
CL - Cile 2
ES - Italia 2
NG - Nigeria 2
TT - Trinidad e Tobago 2
EG - Egitto 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MA - Marocco 1
MT - Malta 1
MX - Messico 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 12.963
Salva come PNG Salva come JPEG
Città #
Chandler 1.086
Jacksonville 958
Dublin 933
Singapore 811
Princeton 383
Ashburn 378
Southend 370
Izmir 335
Nanjing 235
Dearborn 205
Beijing 185
Wilmington 185
Santa Clara 169
Cambridge 159
Ann Arbor 144
Altamura 134
Chieti 104
Nanchang 99
Boardman 88
New York 69
Washington 63
Los Angeles 58
Helsinki 56
Shenyang 49
Hebei 48
Kunming 47
Woodbridge 44
Tianjin 42
Munich 32
Changsha 31
Jiaxing 31
Grevenbroich 30
Norwalk 29
Rome 28
Augusta 25
Moscow 25
Pescara 24
Seattle 20
Dong Ket 18
Jinan 18
Toronto 18
Changchun 17
Lanzhou 17
Milan 17
San Mateo 17
Brussels 16
Hangzhou 16
Falls Church 15
Brno 14
Shanghai 13
Guangzhou 11
Amsterdam 10
Leawood 10
Pune 10
Frankfurt am Main 9
London 9
Caserta 8
Ningbo 8
Romola 7
Tappahannock 7
Wuhan 7
Bologna 6
Hong Kong 6
Kocaeli 6
Lodz 6
Ottawa 6
Taiyuan 6
Teramo 6
Tirana 6
Zhengzhou 6
Fairfield 5
Florence 5
Fuzhou 5
Grugliasco 5
Hefei 5
Naples 5
Orange 5
Paris 5
Ancona 4
Cagliari 4
Campobasso 4
Chicago 4
Delhi 4
Houston 4
Lappeenranta 4
Monmouth Junction 4
Mountain View 4
Palermo 4
Radomsko 4
Reggio Calabria 4
Rotterdam 4
Anzola Dell'emilia 3
Ardabil 3
Catania 3
Chengdu 3
Clifton 3
Denver 3
Edinburgh 3
Kraków 3
Legnano 3
Totale 8.177
Salva come PNG Salva come JPEG
Nome #
Role of growth factors in the development of diabetic complications 129
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus 126
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 124
Pentraxin 3 and platelet activation in obese patients after gastric banding 123
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. 117
Soluble CD40L in Mediterranean Spotted Fever: relation to oxidative stress and platelet activation 115
Variability in the Recovery Rate of Platelet Cyclooxygenase Activity During Chronic Therapy With Low-Dose Aspirin in Type 2 Diabetes. 115
Oxidative-induced membrane damage in diabetes lymphocytes: effects on intracellular Ca2+ homeostasis 113
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 113
Long-term Positivity to SARS-CoV-2: A Clinical Case of COVID-19 with Persistent Evidence of Infection 108
Association of low-grade inflammation and platelet activation in hypertensive patients with microalbuminuria 105
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus 105
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 104
Platelets and Diabetes 104
Neurocognitive impairment and suicide risk among prison inmates 101
Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis 101
Livelli circolanti di adiponectina e interleuchina-10 nell’obesità di tipo androide. 100
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. implications for aspirin 'resistance'. 100
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 100
The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. 100
Determinants of platelet activation in hypertensives with microalbuminuria. 98
Post-traumatic stress in pregnant women with primary cytomegalovirus infection and risk of congenital infection in newborns. 98
Platelets and diabetes mellitus 97
Arterial stiffness and sedentary lifestyle: Role of oxidative stress 95
Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. 95
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. 94
The role of antileukotrienes in the treatment of asthma. 93
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes 93
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin 92
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. 92
CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. 90
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 90
Platelet activation in obesity and metabolic syndrome. 89
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. 89
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. 89
Coagulation and infective endocarditis: sooner or later 89
The role of nitric oxide in the development of diabetic angiopathy. 88
Oxidative stress drivers and modulators in obesity and cardiovascular disease: from biomarkers to therapeutic approach. 88
Atherothrombotic disease and the metabolic syndrome. 87
Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy. 86
Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis. 86
The deadly line linking sympathetic overdrive, dipping status and vascular risk: Critical appraisal and therapeutic implications 85
A case of coinfection with SARS-COV-2 and Cytomegalovirus in the Era of Covid-19 85
Determinants of increased cardiovascular disease in obesity and metabolic syndrome. 85
Circulating Myeloid-Related Protein-8/14 is Related to Thromboxane-Dependent Platelet Activation in Patients With Acute Coronary Syndrome, With and Without Ongoing Low-Dose Aspirin Treatment. 84
Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: Effects of anti-TNFα treatment 83
Soluble forms of RAGE in internal medicine. 83
Circulating CD40 ligand, Dickkopf-1 and P-selectin in HIV-infected patients 83
Soluble forms of RAGE in human diseases: clinical and therapeutical implications. 82
Determinants of the Variability in the Recovery Rate of Platelet Cyclooxygenase Activity during Chronic Therapy with Low-Dose Aspirin in Type 2 Diabetes 82
Insulin resistance as a determinant of platelet activation in obese women. 81
Thromboxane-dependent platelet activation in obese subjects with prediabetes or early type 2 diabetes: Effects of liraglutide-or lifestyle changes-induced weight loss 81
Platelets as a source of CD40 ligand in type 2 diabetes mellitus 81
Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease 81
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 80
Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. 80
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy 80
Decreased plasma soluble rage in patients with hypercholesterolemia: effects of statins. 80
LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro 80
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs 80
Soluble RAGE in type 2 diabetes: association with oxidative stress. 78
From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis 78
Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids 78
Postprandial hyperglycemia is an important determinant of platelet activation. evidence from biochemical measurements and pharmacological intervention with acarbose 77
Determinants of platelet activation in hypertensives with microalbuminuria. 77
Circulating endothelial progenitor cells and low-dose-aspirin-insensitive thromboxane biosynthesis in polycythemia rubra vera. 76
A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction 76
Increased Vascular Endothelial Growth Factor Serum Concentrations May Help to Identify Patients with Onset of Type 1 Diabetes during Childhood at risk for Developing Persistent Microalbuminuria 76
Effects of high-amount-high-intensity exercise on in vivo platelet activation: Modulation by lipid peroxidation and AGE/RAGE axis 76
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 75
Effectiveness of Montelukast versus Budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma 75
Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus 74
Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach 74
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study 74
Aterosclerosi ed aterosclerosi accelerata: ruolo e meccanismi dell’immunoflogosi. 73
Postprandial hyperglycemia is an important determinant of platelet activation in early type 2 diabetes mellitus. Evidence from biochemical measurements and pharmacological intervention with acarbose. 73
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 73
The Coxib case: Are EP receptors really guilty? 72
The left atrial appendage: from embryology to prevention of thromboembolism 72
Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever 72
Nutraceuticals in diabetes and metabolic syndrome. 71
Effects of Acarbose on in Vivo Markers of Oxidative Stress and Platelet Activation in Early Type 2 Diabetes 71
Oxidant stress as a major determinant of platelet activation in invasive breast cancer 71
Unveiling the inflammatory face of antiplatelet drugs. 70
Association between PAI-1 and Oxidative Stress in Android Obesity 70
CD40 ligand and MCP-1 levels as predictors of cardiovascular events in lacunar and non-lacunar strokes. 70
Enhanced soluble CD40 Ligand is responsible for endothelial dysfunction and monocyte activation in patients with diabetes mellitus. Effect of improved metabolic control. 70
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. 70
Attivazione piastrinica e stress ossidativo in vivo nell’artrite reumatoide. 70
Aspirin, platelets, and cancer: The point of view of the internist. 70
Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study 70
TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. 69
Antiplatelet Agents. Thromboxane receptors antagonists and/or synthase inhibitors 69
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper 69
Oxidative stress in chronic vascular disease: From prediction to prevention 69
Aspirin as antiplatelet agent in diabetes. PROS-. 69
Thrombin as a common downstream target blocking both platelet and monocyte activation 68
Circulating MRP 8/14 is Associated with Thromboxane Dependent Platelet Activation in NSTEMI Patients: Effect of Aspirin Treatment 68
Decreased plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus: association with oxidative stress and metabolic control. 68
Soluble CD40L as an indicator of platelet Activation in Heart Failure 68
Totale 8.566
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.142
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.298 0 0 0 0 0 141 290 227 89 294 235 22
2020/20211.105 191 17 202 20 58 242 31 28 102 140 38 36
2021/20221.005 29 26 10 175 76 43 39 75 97 55 112 268
2022/20232.957 232 426 180 284 276 596 160 240 377 36 86 64
2023/20241.741 104 44 119 51 131 551 363 107 39 51 25 156
2024/20251.869 242 703 577 88 92 167 0 0 0 0 0 0
Totale 14.030